Abstract Treatment of lung cancer remains a challenge, and lung cancer is still the leading
cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but …

Introduction Non-small cell lung cancer (NSCLC) is often diagnosed in advanced stages
and is associated with poor outcomes. Existing standards of care for NSCLC result in low …

Survival rates for metastatic lung cancer including non-small cell lung cancer (NSCLC) and
small cell lung cancer (SCLC) are poor with 5-year survival of less than 5%. The use of …

Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of
patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective …

Among several types of tumor, lung cancer is considered one of the most fatal and still the
main cause of cancer-related deaths. Although chemotherapeutic agents can improve …

Background Lung cancer is the most common cause of cancer-related death in the United
States, yet traditional chemotherapy fails to provide long-term benefit for many patients. New …

Lung cancer has the highest incidence of morbidity and mortality throughout the globe. A
large number of patients are diagnosed with lung cancer at the later stages of the disease …

Historically, non-small-cell lung cancer (NSCLC) has been regarded as a nonimmunogenic
tumor; however, recent studies have shown that NSCLCs are among the most responsive …

For advanced metastatic non-small-lung cancer, the landscape of actionable driver
alterations is rapidly growing, with nine targetable oncogenes and seven approvals within …

Methods of harnessing the immune system to treat cancer have been investigated for
decades, but yielded little clinical progress. However, in recent years, novel drugs that allow …